Case: Patient 2, female, 9.6yo

DiseaseAssertion: VWD2A

FamilyInfo: NA

ParentalGenotype(s): NA

CasePresentingHPOs: HP:0012147, HP:0030129, HP:0030130, HP:0030132

(Reduced quantity of VWF, impaired ristocetin cofactor assay activity, Impaired von Willebrand factor collagen binding activity, Absence of large von Willebrand factor multimers)

CaseHPOFreeText: VWF:Ag = 27%, undetectable VWF:RCo and VWF:CB; Platelets (*109/L) = 274, Mean Platelet Volume (fL) = 10, FVIII:C (\%) = 34, VWF:CB (\%) <5, VWF:RCo (\%) = <5, aPTT (sec) = 51.6, PT (\%) =724

CaseNOTHPOs: HP:0001873

(Thrombocytopenia)

CaseNOTHPOFreeText:

CasePreviousTesting: NA

GenotypingMethod: sequencing of exon 28 of the VWF

PreviouslyPublished: NA

Gene: VWF

Variant: c.4373G>A (p.Cys1458Tyr)

HGVS: NM_000552.4(VWF):c.4373G>A (p.Cys1458Tyr)

ClinVarID: 100351; https://www.ncbi.nlm.nih.gov/clinvar/variation/100351/

CAID: NA

gnomAD: absent

Case: IP #38 in type U VWD sub-cohort

DiseaseAssertion: unclassified (2A/2B) VWD

FamilyInfo:

ParentalGenotype(s):

CasePresentingHPOs:

CaseHPOFreeRext: VWF:Ag [IU/dL] = 19; VWF:Ac [IU/dL] = 1; FVIII:C [IU/dL] = 27

CaseNOTHPOs:

CaseNOTHPOFreeText:

CasePreviousTesting:

GenotypingMethod: Sequence variations in the VWF were identified through direct sequencing, while the detection of large rearrangements utilized the multiplex ligation-dependent probe amplification (MLPA) technique or assessed copy number variations (CNVs). Sanger sequencing methodology was applied for VWF analysis in patients investigated prior to 2016 (approximately 14% of IPs), whereas next-generation sequencing (NGS) was employed for the analysis of VWF in patients inspected from 2017 onwards (about 86% of IPs). In both strategies, the entire VWF, encompassing all 52 exons, intron/exon boundaries, and promoter regions, was analyzed.

PreviouslyPublished:

Gene: VWF

Variant: c.4373G>A p.Cys1458Tyr

HGVS:

ClinVarID: 100351

CAID:

gnomAD: absent